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NEW IN 2017, UPDATE OF POLISH FORUM  
FOR PREVENTION GUIDELINES ON DIABETES
1. Updated recommendations for the screening of diabetes
2. The role of glycated haemoglobin (HbA1c) in diagnosis 
of diabetes
3. Sodium-glucose co-transporter-2 (SGLT2) inhibitors or 
glucagon-like peptide 1 (GLP-1) agonists to be consid-
ered in patients with diabetes and cardiovascular disease 
(CVD)
4. New treatment goals
1. CRITERIA FOR THE DIAGNOSIS  
OF CARBOHYDRATE ABNORMALITIES
Diabetes mellitus [1–3]:
 — A random glycaemia ≥ 11.1 mmol/L (200 mg/dL) in 
patients with the symptoms of hyperglycaemia (exces-
sive thirst, polyuria, weakness, decreased body mass) or
 — A fasting glycaemia ≥ 7.0 mmol/L (126 mg/dL) in two meas-
urements irrespective of the symptoms of hyperglycaemia or
 — A glycaemia > 11.1 mmol/L (200 mg/dL) at 120 min after 
a 75-g oral glucose tolerance test (OGTT).
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Pre-diabetes [1–3]:
 — Impaired fasting glucose*: 5.6–6.9 mmol/L (100– 
–125 mg/dL) after overnight fast and < 7.8 mmol/L 
(140 mg/dL) at 120 min of OGTT
 — Impaired glucose tolerance: 7.8–11.0 mmol/L (140– 
–199 mg/dL) at 120 min of OGTT.
Diabetes in a patient treated with  
metformin because of prediabetes [2]:
 — Glucose ≥ 11.1 mmol/L (200 mg/dL) in 120 min of OGTT 
provided the discontinuation of metformin for at least 
a week before the OGTT.
Diabetes based on HbA1c** [2]:
 — Currently in Poland it is not recommended that HbA1c 
be used alone for the diagnosis of diabetes (no standard-
ised method of determination and the threshold value 
of HbA1c).
*It is recommended that glucose concentration be determined 
in venous plasma in a laboratory covered by an external quality 
control. Assays performed using glucose meters should not be 
used for diagnostic purposes [2].
**Since 2010, the American Diabetes Association (ADA) al-
lows determination of HbA1c for the diagnosis of diabetes and 
pre-diabetes. HbA1c ≥ 6.5% ratio is considered as the thresh-
old value for the diagnosis of diabetes; in turn, pre-diabetes is 
diagnosed when HbA1c is 5.7–6.4%.
2. PREVALENCE
Currently, 390 million people worldwide have diabetes, and 
this figure will probably increase by another 200 million over 
the next 20 years. In Poland, diabetes has been diagnosed in 
about 2,100,000 people. Given the number of undiagnosed 
people in our country, this disease affects about three million 
people. The prevalence of diabetes among Polish adults is 
nearly 7% while impaired glucose intolerance is nearly 16%. 
In the age group 45–74 years, the prevalence of diabetes is 
approximately 16% in men and 12% in women [4].
3. DIABETES AND RISK OF CVD
Type 2 diabetes mellitus and type 1 diabetes mellitus with ne-
phropathy increase the risk of atherosclerotic CVD — 2–3 fold 
in men and 3–5 fold in women. Prediabetes also contributes 
to the increased risk. Glycaemia after an OGTT is a better 
marker of CVD risk than fasting glycaemia. Type 2 diabetes 
mellitus and pre-diabetes are frequently associated with other 
modifiable atherosclerotic risk factors: arterial hypertension, 
lipid disorders, and obesity [1, 3, 5].
4. SCREENING
Screening for diabetes should be performed in women and 
men > 45 years of age, and irrespectively of age in patients 
with the following risk factors: overweight or obesity (body 
mass index ≥ 25 kg/m2 and/or waist circumference; ≥ 80 cm 
in women, ≥ 94 cm in men), familial diabetes (parents or sib-
lings), sedentary lifestyle, previous abnormal fasting glycaemia 
or glucose intolerance, dyslipidaemia (high-density lipoprotein 
cholesterol < 1 mmol/L [40 mg/dL] for both sexes and/or tri-
glycerides ≥ 1.7 mmol/L [150 mg/dL]), arterial hypertension, 
CVD, cystic fibrosis (in patients ≥ 10 years old), and in women 
a history of pregnancy-induced diabetes, polycystic ovarian 
syndrome, and delivery of baby weighting > 4 kg [1–3, 5].
The first-line investigation should be the determination of 
fasting blood glucose levels. In patients with abnormal fasting 
glycaemia 5.6–6.9 mmol/L and in patients with normal blood 
glucose levels but with CVD, metabolic syndrome, glycosuria, 
in pregnant women and in the elderly an OGTT is recom-
mended as an additional investigation*** [1, 3, 6].
Any patient with acute coronary syndrome (ACS), except 
for patients previously diagnosed with diabetes, should be sub-
jected to OGTT not earlier than 4–5 days after the ACS [2, 3].
Screening should be conducted within the existing health 
care system by primary care physicians. 
***Some international scientific societies recommend that 
patients with known CVD should have the screening started 
with both the total HbA1c and plasma glucose fasting, and in 
case of doubt, OGTT should be performed [6].
5. THE EFFECTS OF GLYCAEMIC CONTROL
Successful treatment of type 1 diabetes mellitus, i.e. main-
taining near-normoglycaemia, results in a 2-fold decrease in 
the risk of CVD morbidity and mortality and reduces the risk 
of the development and progression of diabetic retinopathy, 
nephropathy, and neuropathy. In subjects with type 2 diabetes 
a 1% reduction of HbA1c is associated with a 37% reduction 
in microangiopathic complications, a 14% reduction in myo-
cardial infarction, a 12% reduction in stroke, a 16% reduction 
in heart failure, and a 21% reduction in diabetes-related death. 
In patients with type 2 diabetes lasting > 10 years with a high 
percentage of HbA1c, with CVD, or high cardiovascular risk, 
too strict metabolic control may increase the risk of death. In 
type 2 diabetes beneficial effects of metformin on the risk of 
CVD and death have been observed. In overweight or obese 
people with impaired glucose tolerance regular physical activity 
and weight reduction of 5–10% decreased the risk of develop-
ing type 2 diabetes by nearly 60% [1, 3, 5].
6. TREATMENT — EDUCATION,  
LIFESTYLE CHANGE
In people with diabetes and the pre-diabetic states, we rec-
ommended: education, implementation of intensive lifestyle 
changes (diet, regular physical activity, weight reduction, 
smoking cessation), and the control and treatment of other 
cardiovascular risk factors — hypertension and lipid disorders. 
Physical activity is an integral part of diabetes manage-
ment. In order to achieve optimal effect, physical activity 
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should be regular, preferably daily. The intensity of exercise 
should be determined by the physician on the basis of a com-
plete clinical picture and the current lifestyle of the patient. 
Currently, it is recommended to have a minimum of 150 min 
of moderate to high intensity physical activity per week when 
no other contraindications occur [1–3].
7. TREATMENT — DIETARY  
RECOMMENDATIONS
The calorific value and composition of food should be taken 
into account: carbohydrates 40–50% (glycaemic index < 50), 
fats 30–35% (saturated fats < 10%, in patients with low-den-
sity lipoprotein > 2.6 mmol/L [100 mg/dL] < 7%, trans 
fats < 1%), and protein 15–20% of the caloric value. The 
recommended level of salt intake is 5–6 g/day (≤ 4.8 g/day 
in people with moderate hypertension, ≤ 4 g/day in patients 
with hypertension and nephropathy). It should be emphasised 
that the optimum proportions of macronutrients in the diet 
should be determined individually, taking into account the 
clinical aspects of the patient [1–3, 5].
8. TREATMENT — PHARMACOTHERAPY
Pharmacological treatment should be done under the supervi-
sion of physicians specialising in the treatment of diabetes. In the 
pharmacological treatment of hyperglycaemia in type 2 diabetes 
several factors should be considered, namely insulin resistance 
and insulin secretion disorders, fasting and postprandial gly-
caemia, and the progressive character of the disease [1–3, 5]. 
The drug of choice for initiation of pharmacotherapy in type 2 
diabetes is metformin, while several options exist for the in-
tensification of this treatment. SGLT2 inhibitors, particularly 
empagliflozin, or GLP-1 agonists, particularly liraglutide, should 
be considered in patients with CVD [5]. To achieve metabolic 
control, treatment with oral drugs should be intensified and if 
necessary followed by insulin therapy [1–3, 5].
Antiplatelet therapy (e.g. with aspirin) is not recom-
mended for people with diabetes mellitus, who do not have 
CVD. All patients > 40 years of age and selected younger pa-
tients at elevated risk are recommended for statin therapy [5].
9. TREATMENT GOALS OF DIABETIC PATIENTS
In the management of diabetes all target values for carbo-
hydrates, lipids, blood pressure, and body mass should be 
achieved. Treatment should be tailored to the patient’s needs, 
taking into account hypoglycaemia risk and patient education. 
In some cases, achieving the therapeutic objective may be 
difficult, and these patients should strive to get as close to the 
presented goals of treatment as possible (Table 1) [1–3, 5].
Table 1. Treatment goals of diabetic patients
Treatment goals of diabetic patients Type 1 Type 2
HbA1c (%)* ≤ 7.0# ≤ 7.0**
Fasting and preprandial glucose level [mmol/L (mg/dL)] 4.4–6.1 (80–110) –
Postprandial glucose level [mmol/L (mg/dL)] < 7.8 (140) –
Blood pressure [mm Hg]: 
Major criterion < 140/85
Specific criteria < 130/80 in patients with type 1 diabetes mellitus and in selected patients  
with type 2 diabetes mellitus, e.g. younger patients at elevated risk for stroke, 
retinopathy, albuminuria 
120/75–80 in younger type 1 diabetes mellitus patients (< 40 years of age)  
with persistent microalbuminuria
< 150/90 in patients > 80 years of age, unless renal impairment is present
Total cholesterol [mmol/L (mg/dL)] < 4.5 (175)
LDL-C [mmol/L (mg/dL)] < 1.8 (70) or a reduction of at least 50% if the baseline LDL-C is  
between 1.8 and 3.5 (70–135) — very high-risk patients 
< 2.6 (100) or a reduction of at least 50% if the baseline LDL-C is  
between 2.6 and 5.1 (100–200) — high-risk patients
HDL-C [mmol/L (mg/dL)] > 1.0 (40) for men, > 1.3 (50) for women
Non-HDL-C [mmol/L (mg/dL)] < 2.6 (100) — very high-risk patients 
< 3.3 (130) — high-risk patients
Triglycerides [mmol/L (mg/dL)] < 1.7 (150)
#HbA1c < 6.5 for patients with low risk of hypoglycaemia; *Analytic method certified by National Glycohaemoglobin Standardisation Programme 
(NGSP); **HbA1c ≤ 6.5 in case of short lasting type 2 diabetes; HbA1c < 8.0% in patients with advanced age and/or with macrovascular compli-
cations of diabetes (myocardial infarction and/or stroke) and/or multiple comorbidities [2]; HDL-C — high-density lipoprotein cholesterol;  
LDL-C — low-density lipoprotein cholesterol
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10. CONTROL AND MONITORING
It is recommended that systematic glycaemic control be pro-
vided with HbA1c, which reflects the average blood glucose 
over the previous three months. An important part of diabetes 
treatment is self-control. The frequency of the recommended 
blood glucose monitoring depends on diabetic treatment. 
HbA1c should be performed at least once a year in patients 
with stable course of diabetes, who achieve treatment goals, 
or once every three months when treatment goals are not 
achieved and/or in the case of a change of treatment [1–3, 5].
Blood pressure should be measured during every routine 
follow-up visit [1–3].
In type 2 diabetes it is recommended to determine lipid 
values at the moment of diagnosis, and then once a year in 
the case of normolipidaemia or more frequently if necessary 
until the target values are achieved. In type 1 diabetes, lipid 
levels should be monitored every 2–5 years depending on 
CVD risk. In diabetic patients, the control should include 
a full lipid profile [1, 2].
During every follow-up visit body mass should be measured, 
self-monitored preprandial and postprandial glycaemia should 
be checked, and patients should receive education and be 
motivated to comply with treatment and lifestyle changes [1, 2].
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